Cell and gene therapies are finally becoming viable patient treatment options, with both T
cell-and hematopoietic stem cell (HSC)-based therapies being approved to market in …

Ex vivo transduction of human CD34+ hematopoietic stem/progenitor cells (hCD34+
HSPCs) and T lymphocytes is a key process that requires high efficiency and low toxicity to …

Gene transfer into hCD34+ hematopoietic stem/progenitor cells (HSCs) using human
immunodeficiency virus type 1 (HIV-1)-based lentiviral vectors (LVs) has several promising …

Gene delivery into hCD34+ hematopoietic stem/progenitor cells (HSPCs) using human
immunodeficiency virus, type 1-derived lentiviral vectors (LVs) has several promising …

Viruses have been repurposed into tools for gene delivery by transforming them into viral
vectors. The most frequently used vectors are lentiviral vectors (LVs), derived from the …

Retroviral vectors are presently amongst the most widely used vectors in gene therapy
clinical trials to target pathologies of different origins, such as cancers, genetic diseases or …

Correction of patient-specific induced pluripotent stem cells (iPSC) upon gene delivery
through retroviral vectors offers new treatment perspectives for monogenetic diseases. Gene …

Chimeric antigen receptor (CAR)-modified T cells have revealed promising results in the
treatment of cancer, but they still need to overcome various hurdles, including a complicated …

Ex vivo retroviral gene transfer into CD34+ hematopoietic stem and progenitor cells
(HSPCs) has demonstrated remarkable clinical success in gene therapy for monogenic …

Lentiviral vectors have emerged as an efficient, safe therapeutic tool for gene therapy based
on hematopoietic stem cells (HSCs) or T cells. However, the monitoring of transduced cells …